Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 12/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | SPHK1 | Q9NYA1 | 12/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.36 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | METTL3 | Q86U44 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6377060 | 1.00 | SPHK2 (0.41) | SPHK2JAK2JAK1TYK2JAK3 | |
| SCHEMBL5035995 | 0.90 | SPHK2 (0.53) | SPHK2SPHK1SCN7AKCNH2 | |
| SCHEMBL5035994 | 0.90 | SPHK2 (0.53) | SPHK2SPHK1SCN7AKCNH2 | |
| SCHEMBL5040525 | 0.90 | SPHK2 (0.53) | SPHK2SPHK1SCN7AKCNH2 | |
| SCHEMBL5523005 | 0.87 | SPHK2 (0.49) | SPHK2SPHK1ACVR1SCN7AKCNH2 | |
| SCHEMBL5523009 | 0.87 | SPHK2 (0.49) | SPHK2SPHK1ACVR1SCN7AKCNH2 | |
| SCHEMBL5037485 | 0.87 | ALOX5AP (0.35) | SPHK2SPHK1ACVR1 | |
| SCHEMBL5037480 | 0.87 | ALOX5AP (0.35) | SPHK2SPHK1ACVR1 | |
| SCHEMBL5529499 | 0.86 | SPHK2 (0.41) | SPHK2SPHK1ACVR1 | |
| SCHEMBL5529495 | 0.86 | SPHK2 (0.41) | SPHK2SPHK1ACVR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1395564-B1 | QUINOLINE DERIVATIVES AS LIGANDS FOR THE NEUROPEPTIDE Y RECEPTOR | HOFFMANN LA ROCHE (CH) | 2008-02-27 | — | — | EP | disclosed |
| US-20050049413-A1 | Quinoline derivatives | MUELLER WERNER (CH) | 2005-03-03 | — | — | US | disclosed |
| US-6818767-B2 | NEUROPEPTIDE Y (NPY) ANTAGONISTS FOR THE TREATMENT OR PREVENTION OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, RENAL FAILURE, EATING DISORDERS, OR OBESITY | HOFFMANN-LA ROCHE INC. | 2004-11-16 | — | — | US | disclosed |
| US-20020198194-A1 | Quinoline derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198194-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | SPHK2 3483/4885JAK2 232/4885JAK1 1251/4885 |
| US-20050049413-A1 | Quinoline derivatives | NPY2R, NPY1R, NPY4R | SPHK2 3483/4885JAK2 232/4885JAK1 1251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.